Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Health Infrastructure topic
No spam. Unsubscribe anytime.
Stakeholders defend New Hampshire Vaccine Association as lawmakers seek greater transparency
Summary
HB524 would tighten reporting and create a study committee to examine the New Hampshire Vaccine Association (NHVA). Supporters warn a committee is unnecessary because the association reports annual savings and low administrative costs; some lawmakers called for more transparency on fund balances and pricing.
Representative Bob Wary (presenting for the prime sponsor) asked the committee to support HB524, a bill that would adjust deposit/disbursement language for the New Hampshire Vaccine Association and create a study committee to review operational practices and funding needs.
Physicians, NHVA board members and DHHS staff generally defended the association. DHHS staff told the committee the partnership saves the state roughly 30% on vaccine purchases for privately insured children and that the NHVA has administrative expenses under 1% of purchases. Several clinicians told lawmakers the NHVA enables clinics and families to receive vaccines at no cost and that removing the program or disrupting it would raise costs and logistical burdens for pediatric practices.
Critics on the record urged clarity on leftover fund balances, administrative fees and whether similar arrangements used for adult vaccines might be appropriate. Representative Lucy Weber and others asked for more precise financial detail. NHVA supporters said annual mandatory reports to the governor and legislative leaders provide oversight and that the program is a longstanding public‑private partnership valued by providers and payers.
What happens next: Committee members debated whether a study committee is necessary given existing annual reporting. Lawmakers asked for data on funds returned and historical balances; the association and DHHS said they could provide additional documentation.
Provenance: topic recorded from SEG 2961 (intro) through SEG 3352 (public/official testimony).
